SCHEMBL1024266

SCHEMBL1024266

Cc1cc(N2CCOCC2)c(Br)cc1NC(=O)O

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
ACP1 P24666 2/20 0.44
HPGD P15428 1/20 0.44
MAPT P10636 1/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
NPSR1 Q6W5P4 2/20 0.44
RAB9A P51151 1/20 0.43
POLB P06746 2/20 0.43
ABCC1 P33527 1/20 0.42
PKM P14618 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
LMNA P02545 1/20 0.41
TSHR P16473 1/20 0.41
ATM Q13315 1/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13622521 0.85 PRKDC (0.45) ALDH1A1ACP1MAPTMEN1KMT2A
SCHEMBL21382342 0.84 ALDH1A1 (0.48) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL13670056 0.82 ALDH1A1 (0.40) ALDH1A1ACP1MAPTMEN1KMT2A
SCHEMBL29788590 0.74 MAPT (0.51) ALDH1A1HPGDMAPTMEN1KMT2A
SCHEMBL1026760 0.74 MAPT (0.51) ALDH1A1HPGDMAPTMEN1KMT2A
SCHEMBL21382557 0.72 GAA (0.49) ALDH1A1MAPTMEN1KMT2ARAB9A
SCHEMBL4326786 0.72 ALDH1A1 (0.70) ALDH1A1HPGDMEN1KMT2APOLB
SCHEMBL20085045 0.71 ALDH1A1 (0.37) ALDH1A1ACP1HPGDMAPTMEN1
SCHEMBL1026474 0.71 ALDH1A1 (0.40) ALDH1A1HPGDMEN1KMT2ANPSR1
SCHEMBL1023637 0.71 KMT2A (0.46) ALDH1A1MEN1KMT2ANPSR1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
EP-2274288-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Incyte Corporation (US) 2011-01-19 EP disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK ALDH1A1 2511/4885ACP1 176/4885HPGD 4536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.